Canada Markets closed

Orchard Therapeutics plc (ORTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.0100-0.0600 (-5.61%)
At close: 04:00PM EST
1.0200 +0.01 (+0.99%)
After hours: 06:48PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close1.0700
Open1.0700
Bid1.0000 x 1200
Ask1.0400 x 1400
Day's Range0.9800 - 1.0800
52 Week Range0.9800 - 9.0800
Volume932,964
Avg. Volume1,013,059
Market Cap126.754M
Beta (5Y Monthly)1.11
PE Ratio (TTM)N/A
EPS (TTM)-1.2120
Earnings DateFeb. 28, 2022 - Mar. 04, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.31
  • GlobeNewswire

    Orchard Therapeutics Announces Publication in The Lancet of Long-term Clinical Outcomes with Libmeldy for the Treatment of Children with Early-onset MLD

    Administration of one-time hematopoietic stem cell (HSC) gene therapy resulted in sustained, clinically meaningful benefits by preserving cognitive function and motor development in most patients 90% overall survival with up to 7.5 years of follow-up (median 3.2 years) in 29 patients BOSTON and LONDON, Jan. 21, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced the publication in The Lancet of long-term clinical outcomes evaluating the saf

  • GlobeNewswire

    Orchard Therapeutics Announces Recent Commercial and Regulatory Progress for Late-stage HSC Gene Therapy Programs and Outlines Key 2022 Milestones

    Launch Momentum Building for Libmeldy® in Europe with Health Technology Assessments Progressing Favorably and Treatment Underway for Multiple Commercial Patients Initiating U.S. BLA Submission for OTL-200 as Early as Year End 2022; Constructive CMC Meeting with FDA Supports Timeline EU MAA Submission for OTL-103 in Wiskott-Aldrich Syndrome Expected in Mid-2022 Following Productive Regulatory Interactions Ended 2021 with approximately $220M in Cash and Investments to Support Operations into the F

  • GlobeNewswire

    Orchard Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

    BOSTON and LONDON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company is scheduled to present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Thursday January 13, 2022, at 9:00 a.m. ET. A live webcast of the presentation and breakout session will be available under "News & Events" in the Investors & Media section of the company's website at www.orchard-tx.com. Webcast replays will be archived on th